Grossi Federico 4
4 · Apellis Pharmaceuticals, Inc. · Filed May 3, 2022
Insider Transaction Report
Form 4
Grossi Federico
See Remarks
Transactions
- Other
Common Stock
2022-04-21−1,875→ 114,561 total - Sale
Common Stock
2022-05-02$43.56/sh−2,500$108,900→ 112,061 total - Other
Stock Option (Right to Buy)
2022-04-21−11,250→ 0 totalExercise: $44.90Exp: 2031-01-27→ Common Stock (11,250 underlying)
Footnotes (4)
- [F1]This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
- [F2]This is a scheduled sale from 10B5-1 trading plan.
- [F3]This represents the cancellation of a performance stock option granted on 01/28/01. The performance metrics were not met.
- [F4]This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.